Oxford Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Oxford Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$411K	Buy	+1,364	New	+$411K	0.2%	139
2026 Q1	–	Sell	-2,534	Closed	-$1.01M	–	472
2025 Q4	$1.01M	Sell	2,534 -816	-24%	-$361K	0.36%	63
2025 Q3	$1.53M	Buy	3,350 +882	+36%	+$359K	0.5%	34
2025 Q2	$805K	Buy	+2,468	New	+$683K	0.26%	90
2024 Q2	–	Sell	-1,344	Closed	-$201K	–	280
2024 Q1	$201K	Sell	1,344 -1,720	-56%	-$287K	0.21%	192
2023 Q4	$586K	Buy	+3,064	New	+$522K	0.88%	27
2020 Q1	–	Sell	-10,412	Closed	-$1.2M	–	258
2019 Q4	$1.2M	Buy	10,412 +6,569	+171%	+$655K	0.03%	752
2019 Q3	$309K	Buy	+3,843	New	+$304K	0.01%	1445
2017 Q1	–	Sell	-19,723	Closed	-$738K	–	1388
2016 Q4	$738K	Sell	19,723 -21,260	-52%	-$890K	0.03%	528
2016 Q3	$2.78M	Buy	+40,983	New	+$2.89M	0.09%	322
2016 Q1	–	Sell	-79,126	Closed	-$7.41M	–	788
2015 Q4	$7.41M	Buy	79,126 +55,296	+232%	+$5.13M	0.17%	118
2015 Q3	$1.92M	Buy	+23,830	New	+$2.65M	0.06%	295
2015 Q1	–	Sell	-49,594	Closed	-$4.89M	–	659
2014 Q4	$4.89M	Buy	+49,594	New	+$4.59M	0.11%	207
2013 Q4	–	Sell	-249,183	Closed	-$15.9M	–	686
2013 Q3	$15.9M	Buy	249,183 +99,592	+67%	+$4.96M	0.36%	38
2013 Q2	$4.64M	Buy	+149,591	New	+$3.98M	0.13%	260

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oxford Asset Management's ALNY Position: Q2 2026 in Review

Oxford Asset Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 1,364 shares worth $411K. The stake represents 0.2% of the portfolio and ranks #139 among its holdings. This is a return to the name: Oxford Asset Management previously reported a position in ALNY as recently as Q4 2025.

Oxford Asset Management first reported a position in ALNY in Q2 2013 and has held it in 15 quarters since. The position peaked at $15.9M in Q3 2013. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Oxford Asset Management held 1,364 shares of Alnylam Pharmaceuticals worth $411K as of Q2 2026.
Alnylam Pharmaceuticals was a new Oxford Asset Management position in Q2 2026.
Alnylam Pharmaceuticals made up 0.2% of Oxford Asset Management's portfolio in Q2 2026, its #139 holding.
Oxford Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
Oxford Asset Management's Alnylam Pharmaceuticals position peaked at $15.9M in Q3 2013.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.